SupplySide Global
Aquanova to Spotlight Clinical Research, White Label Innovations
New developments include research on NovaSol Curcumin, Boswellia, and vitamin D3 for joint health, and on NovaSol Q10 for energy.
By: Mike Montemarano
Associate Editor, Nutraceuticals World
Photo: katestudio | Adobe Stock
Aquanova, a company specializing in bioavailability enhancement, will showcase its latest clinical research and product innovations at SupplySide Global. The company will highlight its key initiatives, including clinical studies validating NovaSol Curcumin for mobility and NovaSol Q10 for energy. The company will also showcase its white-label finished product offerings.
Mobility
A randomized, placebo-controlled human clinical study is underway to evaluate NovaSol Curcumin in combination with Boswellia and vitamin D3 for inflammation support, mobility, and endurance. The 60-day study will enroll 54 adults with elevated inflammatory markers.
Primary endpoints include changes in the inflammatory markers IL-6, TNF-a, CRP, and ESR. Secondary endpoints include functional mobility assessed via WOMAC scores, safety, and tolerability.
The trial directly compares NovaSol to native compounds, competing products, and a placebo. Results are expected in Q1 2026.
Energy
The company is also conducting an open-label, randomized, single-dose crossover trial assessing the bioavailability of NovaSol Q10 compared to native CoQ10 in healthy adults. The study will enroll 36 participants and measure pharmacokinetic parameters (Cmax, AUC) under fasting conditions with samples collected over 72 hours.
The study will evaluate absorption and exposure, with secondary endpoints monitoring safety and tolerability. Results are expected in Q4 of this year.
White Label Product Line
Aquanova is introducing the NovaSol White Label initiative, a portfolio of ready-to-market supplements. The products incorporate Aquanova’s patented micelle technology with clinically studied ingredients such as curcumin, astaxanthin, CoQ10, and Boswellia in softgel and liquid capsule formats.
“Our mission has always been to set the standard in bioavailability, ensuring that clinically relevant doses translate into meaningful outcomes,” said Frank Behnam, CEO, Aquanova. “At SupplySide Global, we’re excited to showcase both the clinical evidence pipeline and practical product solutions that empower our partners to succeed.”
To learn more, schedule a meeting in advance of the show with Matt Braman ([email protected]), senior director of business development.


